港版氢化可的松片可用来治疗什么病症

It is a glucocorticoid secreted by the adrenal cortex. It is currently mainly used for the replacement treatment of adrenal insufficiency and the treatment of congenital adrenal hyperplasia. Adrenocortical insufficiency can be divided into primary and secondary according to the cause, and acute and chronic according to the course of the disease. The most common form of primary adrenal insufficiency is Addison's disease. Treatment of adrenal insufficiency includes emergency treatment during adrenal crisis and usual hormone replacement therapy, as well as treatment of the cause.

The clinical trial selected 60 patients with hypercortisolism to explore the application and efficacy of two oral hormones, hydrocortisone and prednisone, in postoperative hormone replacement therapy in patients with hypercortisolism. The results showed that hydrocortisone and prednisone, two oral hormones, are safe and effective in postoperative hormone replacement therapy in patients with hypercortisolism.

Research has found that hydrocortisone tablets have a positive therapeutic effect on rheumatic fever, rheumatoid arthritis, gout, allergic diseases, bronchial asthma, severe infections and anti-shock treatment. In the clinical treatment of septic shock in children, the combined use of hydrocortisone and anisodamine can achieve higher efficacy than the single use of hydrocortisone, with fewer adverse reactions, and is worthy of promotion and application.

The therapeutic effect is inseparable from the correct use method. The recommended dose of hydrocortisone tablets for adult patients to treat adrenal insufficiency is 20-30 mg daily, 2/3 taken in the morning and 1/3 after lunch. When there is stress, the dosage should be increased appropriately, up to 80mg per day, taken in divided doses. The dosage of hydrocortisone for pediatric patients is 20-25/m2 per day based on body surface area, divided into 3 times, taken once every hour. Patients should strictly follow medical advice when using it.

Recommended related hot articles: /newsDetail/93293.html